The FDA informed the company...that the HIV BLA did NOT contain certain information needed to complete a substantive review and therefore advised that the "third party" submission was not properly performed and required REsubmission...Cytodyn has disengaged Amarex... and has a global CRO and expects HIV BLA completion in the 1st quarter of 2022.